All In Biotech

Drug Trial Radar · NCT03580564

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

109

Actual

Start

Aug 1, 2018

Primary completion

Aug 22, 2020

Study completion Jan 13, 2022

Sponsor

Sponsor type
Industry
First posted
Jul 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to evaluate the efficacy of KL-A167 a in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification

Conditions

  • Classical Hodgkin Lymphoma

Interventions

  • KL-A167Drug

    KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: Up to 2years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.